Skip to content
Head to head

Maze Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: MAZE · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

MAZE -6.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
MAZEVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price31.37515.02
Change today-3.27%-1.08%
1-year return-11.8%+22.0%
Market cap$1.72B$130.58B
52-week range21.95 – 53.65412.27 – 568.67
Valuation
P/E (TTM)-11.6933.14
P/E percentile, own 5-yr range44th99th
P/B4.006.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.6615.32
Net profit (TTM)$-145.35M$3.88B
Revenue (TTM)$20.00M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-820.8%33.1%
Net margin-757.4%30.7%
Free cash flow (TTM)$-115.26M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership112.4%96.8%
Insider activity (12mo)15 buy / 35 sell28 buy / 22 sell
Short interest (% of float)12.0%1.9%
Analyst consensus100% buy (9)95% buy / 5% hold (21)
Analyst price target$62 (+97%)$624 (+21%)
StockVane view
StockVane Quant RatingD (27)C (68)
Company
Employees1416,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.